Observational Claims Analysis Links Semaglutide Dose Escalation to 6% Lower MACE Risk Versus Tirzepatide Switch
An observational claims study found dose escalation of semaglutide linked to modestly lower cardiovascular risk than switching to tirzepatide; adherence differences and lack of randomization limit causal inference. Head-to-head randomized trials are required to confirm comparative effectiveness.
The retrospective analysis examined 185,705 patients who increased semaglutide to 2 mg and 23,104 who switched to tirzepatide up to 15 mg. At 720-day follow-up, MACE incidence (all-cause death, myocardial infarction, stroke) favored dose escalation by 6% after adjustment for baseline characteristics. This real-world pattern echoes semaglutide's established cardiovascular benefit in the SELECT trial but contrasts with tirzepatide's dual GIP/GLP-1 mechanism that has not yet reported dedicated CV outcomes.
SURPASS-CVOT: tirzepatide will show at least 15% MACE reduction versus placebo by 2027 if primary endpoint met.
Sources (3)
- [1]Primary Source(https://www.komodohealth.com/research)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMoa2307563)
- [3]Supporting Source(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01443-4/fulltext)